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Summary. Mutation analysis was performed for two HFE
mutations (C282Y, H63D) in unrelated patients with
hereditary haemochromatosis (n ¼ 92), family members of
patients (n ¼ 34), and unrelated controls (n ¼ 157) from
Northern Germany. 87/92 patients (94·6%) revealed the
C282Y mutation in homozygous form, five were hetero-
zygous. No H63D mutation was found in 174 chromosomes
of patients homozygous for C282Y, whereas four of the
heterozygote patients also carried the H63D mutation.
Among the control group, 9·6% were heterozygotes for
C282Y. 2/157 subjects were homozygous, 37/157 were
heterozygous for the H63D mutation, but showed no signs of
iron overload.
Keywords: haemochromatosis, C282Y, H63D, German
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Hereditary haemochromatosis (HH) is the most common
genetic disease in Caucasian populations. The affected gene,
HFE, is located on chromosome 6, telomeric to the HLA
region. A single mutation, resulting in a cysteine to tyrosine
substitution at amino acid 282 (C282Y), was found on both
chromosomes in 83% of patients with clinically classified HH
(Feder et al, 1996). The C282Y variant disrupts the inter-
action of the HFE chain with b2-microglobulin (Feder et al,
1997) and prevents the association of the HFE protein with
transferrin receptor (Feder et al, 1998). A second mutation,
representing a histidine to aspartate substitution at position
63 (H63D), was found in the HFE gene of the normal
population, but not on chromosomes carrying the C282Y
mutation.
The frequency of the H63D mutation is increased in HH
patients heterozygous for the C282Y mutation (Feder et al,
1996). Several reports on the frequency of the two HFE
mutations in patients with HH from different countries have
already been published (Feder et al, 1996; Jazwinska et al,
1996; Jouanolle et al, 1997; Borot et al, 1997; Piperno et al.
1998).
A report from a different part of Germany has been
published recently (Gottschalk et al, 1998). In the present
study we analysed the frequency of the two HFE mutations in
patients and controls from North Germany.
MATERIALS AND METHODS
In the time period between 1993 and 1997 about 600
subjects with a suspected iron overload were studied in our
department. Most of them had a history of increased values
of serum iron or serum ferritin or had a family member
affected with HH. Among these patients, the diagnosis of a
haemochromatosis was established in 92 unrelated subjects
by the presence of at least three of the following criteria: (a)
transferrin iron saturation >62%, serum ferritin >300 mg/l;
(b) liver iron concentration (LIC) of >2000 mg Fe/g wet
weight; (c) hepatic iron index (HI[mg/y] ¼ (LIC/age)) >30;
(d) grade 3 or 4 stainable iron in the liver, (e) >4 g of iron
removed by phlebotomy. Starting from each identified patient,
a family study was performed in all relatives available. In
addition, 157 unrelated healthy volunteers were also studied.
All patients and controls were of German ancestry (at least
three generations) located in Hamburg or in neighbouring
North-German federal states.
Genomic DNA from patients or volunteers was isolated
from EDTA blood samples using the QIAamp Blood Kit
(QIAGEN, Hilden, Germany). The PCR was performed using
primers for the C282Y mutation (forward, 50-GTC ACC TCT
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TCA GTG ACC; reverse, 50-AAT GAG GGG CTG ATC CAG)
and the H63D mutation (forward 50-ATG GGT GCC TCA GAG
CAG; reverse 50-AGT CCA GAA GTC AAC AGT). The ampli-
fied products were digested with SnaBl (MBI Fermentas,
St Leon-Rot, Germany) for the C282Y mutation or with BclI
(MBI Fermentas) for the H63D mutation according to the
manufacturer’s recommendations.
Serum-iron, TIBC and serum ferritin were measured using
routine methods. Liver iron concentrations were measured
non-invasively using a SQUID biomagnetometer (Ferrito-
meter, BTi, San Diego, U.S.A.) as described elsewhere (Fischer
et al, 1992).
RESULTS
Patients
The parameters of iron metabolism were clearly different
between the group of patients and controls (Table I). Of the
patients, 94·6% were homozygous and 4·3% were hetero-
zygous for the C282Y mutation. In the patient group there
was no obvious difference in the range of iron loading
between homozygous (n ¼ 87) and heterozygous (n ¼ 5)
carriers. In 174 chromosomes of patients who were homo-
zygous for the C282Y mutation, no H63D mutation was
found. However, four out of five chromosomes of risk in the
patients with heterozygous C282Y mutation also revealed
the H63D mutation.
Family members
Among family members, nine homozygous and 21 hetero-
zygous carriers for the C282Y mutation were found. 4/26
chromosomes at risk carried the H63D mutation (gene
frequency 0·15), including three subjects with compound
heterozygosity. No differences in transferrin saturation and
serum ferritin were found between C282Y heterozygotes
from the family group and the control group.
Controls
No control subject was found homozygous for the C282Y
mutation. 15/314 chromosomes studied carried the C282Y
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Fig 1. Transferrin saturation and serum
ferritin in control subjects with ‘wild-type’
HFE gene, C282Y (top) or H63D mutations
(bottom). Circles, females; squares, males.
mutation, giving a gene frequency of 0·048. 40/299
chromosomes at risk carried the H63D mutation, giving a
frequency of 0·13 in controls. Two subjects (1·3%) were
homozygous and 23·6% were heterozygous for the H63D
mutation.
Blood values characterizing the individual iron status such
as serum ferritin and transferrin saturation showed no
significant differences between the group of ‘wild-type’ gene
carriers and heterozygous carriers of both the C282Y
mutation and the H63D mutation (Fig 1, Table I).
DISCUSSION
The high frequency (94·6%) of the C282Y mutation in
homozygous form in patients from North Germany is in
good agreement with previous studies in other Caucasian
populations (Feder et al, 1996; Jazwinska et al, 1996;
Jouanolle et al, 1997). The C282Y homozygosity seems to be
lower (about 70%) in iron-loaded patients from Southern
European countries such as France and Italy (Borot et al,
1997; Piperno et al, 1998).
Also similar to other studies, a high number of compound
heterozygotes (4/5) was found in the iron-loaded patients
with heterozygous C282Y (Feder et al, 1996). The reason for
the complete linkage disequilibrium between the C282Y and
the H63D mutation is still unclear at the moment.
In the control group of 157 unrelated subjects, no case
with iron overload and no homozygous C282Y mutation
was found. 15/314 chromosomes carried the C282Y muta-
tion, giving an allelic frequency of 4·8%. Assuming that this
mutation is the only cause for haemochromatosis, one can
calculate for the prevalence of homozygous HH to be 1:440.
This is in perfect agreement with a screening study in 2812
prospective blood donors from Hamburg, in which increased
values of serum iron and/or serum ferritin were used as filter
parameters. A relevant iron overload was found in seven
subjects, giving a prevalence of 1:402 (Nielsen et al, 1995).
Comparing the values for transferrin saturation and
serum ferritin in heterozygote carriers from the family
group and the control group, no differences between both
groups were found (Table I, Fig 1). This indicates that the
‘approved’ haemochromatosis genes in the family group are
not different from ‘by-chance C282Y’ genes in the normal
population. This would support the argument that the
C282Y mutation is the only cause which is sufficient for
haemochromatosis disease.
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Table I. Parameters of iron metabolism in clinically classified unrelated patients with hereditary haemochromatosis, family members, and
controls (mean values 6standard deviation).
Serum ferritin* Transferritin saturation Liver Fe*
Subjects n Age (mg/l) (%) (mg/g)
Patients† 92 49·1 6 12·5 1·087(2·858, 413) 90 6 11 2·16 (3·51, 1·33)
Females 33 49·6 6 12·6 701 (1·721, 286) 88 6 10 2·08 (3·21, 1·35)
Males 59 48·7 6 12·6 1451 (3·471, 607) 96 6 11 2·22 (3·73, 1·32)
Family members‡ 34 40·2 6 21·9 120 (381, 38) 49 6 22 0·44 (0·96, 0·20)
Homozygotes 9 49·8 6 19·4 144 (341, 61) 79 6 16 0·69 (1·29, 0·37)
Heterozygotes 21 35·2 6 22·6 79 (235, 27) 40 6 13 0·37 (0·79, 0·17)
‘Wild type’ 4 46·4 6 14·4 113 (173, 73) 34 6 4 0·41 (0·87, 0·19)
Controls 157 42·3 6 17·1 49 (138, 17) 31 6 13 n.d.
Females 77 41·8 6 17·8 33 (90, 12) 29 6 14 n.d.
Males 80 42·8 6 16·3 75 (183, 31) 33 6 11 n.d.
C282Y (þ/¹) 15 48·1 6 21·8 39 (121, 13) 35 6 18 n.d.
H63D (þ/¹) 34 39·5 6 17·8 38 (119, 12) 31 6 14 n.d.
* Geometric mean and asymmetric widths.
† Values given before treatment.
‡ Classified according to the C282Y mutation.
surface expression. Journal of Biological Chemistry, 272, 14025–
14028.
Fischer, R., Engelhardt, R., Nielsen, P., Gabbe, E.E., Schmiegel, W.H.,
Wurbs, D. & Heinrich, H.C. (1992) Liver iron quantification in the
diagnosis and therapy control of iron overload patients. Biomag-
netism: Clinical Aspects (ed. by M. Hoke et al), pp. 585–588.
Elsevier, Amsterdam.
Gottschalk, R., Seidl, C., Lo¨ffler, T., Seifried, E., Hoelzer, D. &
Kaltwasser, J.P. (1998) HFE codon 63/282 (H63D/C282Y)
dimorphism in German patients with genetic hemochromatosis.
Tissue Antigens, 51, 270–275.
Jazwinska, E.C., Cullen, L.M., Busfield, F., Pyper, W.R., Webb, S.I.,
Powell, L.W., Morris, C.P. & Walsh, T.P. (1996) Haemochromatosis
and HLA-H. Nature Genetics, 14, 249–251.
Jouanolle, A.M., Fergelot, P., Gandon, G., Yaouang, J., LeGall,
J.Y. & David, V. (1997) A candidate gene for hemochromatosis:
frequency of the C282Y and H63D mutations. Human Genetics,
100, 544–547.
Merryweather-Clarke, A.T., Pointon, J.J., Shearman, J.D. & Robson,
K.J. (1997) Global prevalence of putative haemochromatosis
mutations. Journal of Medical Genetics, 34, 275–278.
Nielsen, P., Benn, H.P., Peters, C., Fischer, R., Darda, D., Knoedler, B.,
Gabbe, E.E. & Kuehnl, P. (1995) Iron status in prospective blood
donors. Infusionstherapie und Transfusionsmedizin, 22, (Suppl. 1),
142–144.
Piperno, A., Sampietro, M., Pietrangelo, A., Arosio, C., Lupica, L.,
Montosi, G., Veregani, A., Fraquelli, M., Girelli, D., Pasquero, P.,
Roetto, A., Gasparini, P., Fargion, S., Conte, D. & Camaschella, C.
(1998) Heterogeneity of hemochromatosis in Italy. Gastroenterol-
ogy, 114, 996–1002.
845Short Report
q 1998 Blackwell Science Ltd, British Journal of Haematology 103: 842–845
